FDA Plays

[easymoney123]

PATH...added significant position today. I feel we have a chance of FDA approval, nothing is predictable with the FDA.

Joseph Schwartz with Leerink gives $17 price target with 90% FDA approval on Zelrix. Mr. Schwartz covers biotechnology and was named #1 Stock Picker for Pharmaceuticals in the 2011 FT/StarMine Analyst Awards. In 2010, he earned the Wall Street Journal’s #1 ranking for biotech stock picking as part of its “Best on the Street” analysts survey, which topped his #2 ranking in the Journal’s 2008 “Best on the Street” rankings.

http://pulse.alacra.com/analyst-comments/Joseph_Schwartz-A10635

http://www.leerink.com/equity-research/analyst-bios/joseph-schwartz.aspx